- Respiratory disease focused Verona Pharma said it had commenced a clinical trial to evaluate the efficacy and safety of a dry powder inhaler formulation of a treatment for sufferers of chronic obstructive pulmonary disease.

The RPL554 treatment was an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to have bronchodilator as well as anti-inflammatory properties.

The phase-two study would involve enrollment of around 36 patients.

Data from the single dose part of the study were expected during the first half of 2019.

At 8:10am: [LON:VRP] Verona Pharma PLC share price was 0p at 97.5p

Story provided by